Temporal trends in prevalence of liver cancer and etiology-specific liver cancer from 1990 to 2019 - 28/08/24
, Jia Jia b, 1, Yue Yu c, 1, Hao Lu d, Liwei Zhang e, ⁎ Highlights |
• | Unveiling a global decrease in liver cancer prevalence rates from 1990 to 2019. |
• | Hepatitis B remains the leading cause of liver cancer, though hepatitis C, alcohol, and NASH are on the rise. |
• | Distinct regional trends show the Americas with the highest liver cancer prevalence rates. |
• | Higher liver cancer rates in high-income countries linked to hepatitis C and alcohol use. |
• | Study underscores need for tailored prevention, focusing on vaccination, treatment, and regulation. |
Abstract |
Background |
Liver cancer (LC) remains a major cause of cancer death worldwide. Grasping prevalence trends is key to informing strategies for control and prevention. We analyzed the global, regional and national trends in LC prevalence and its major causes from 1990 to 2019.
Methods |
We obtained LC age-standardized prevalence rate (ASPR) estimates from the Global Burden of Disease study 2019 and assessed trends using Joinpoint regression. LC cases were categorized into those due to hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol use, nonalcoholic steatohepatitis (NASH) and other causes.
Results |
While the ASPR of LC has shown a global decrease, there are specific regions where an increase in ASPR has been observed, with the highest rates in America. HBV remained the leading cause of LC (41.45 %) but significant increases occurred for HCV, alcohol use and NASH. Prevalence correlated with socioeconomic development. High-income countries had higher LC rates from HCV and alcohol but lower HBV-related LC. In high-income nations, LC prevalence climbs; the converse holds in middle- and low-income countries.
Conclusions |
Despite a global ASPR decrease, LC due to HCV, NASH, and alcohol is rising. Prevention strategies must prioritize HBV vaccination, HCV treatment, and alcohol regulation.
Impact |
The study informs targeted LC control policies and emphasizes the importance of continued monitoring and regional cooperation to combat LC.
Le texte complet de cet article est disponible en PDF.Keywords : Liver cancer, Prevalence trends, Joinpoint regression, Global Burden of Disease study 2019, Global health
Abbreviations : AAPC, DALYs, APC, SDI, CI, UI, GBD, LC, LC-HBV, LC-HCV, LC-AU, LC-NASH, LC-OC, ASPR, HBV, HCV, NASH
Plan
Vol 48 - N° 8
Article 102451- octobre 2024 Retour au numéro
Article précédent
- Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis
- Guilherme Grossi Lopes Cançado, Patrícia da Silva Fucuta, Nathalia Mota de Faria Gomes, Cláudia Alves Couto, Eduardo Luiz Rachid Cançado, Debora Raquel Benedita Terrabuio, Cristiane Alves Villela‑Nogueira, Michelle Harriz Braga, Mateus Jorge Nardelli, Luciana Costa Faria, Elze Maria Gomes Oliveira, Vivian Rotman, Maria Beatriz Oliveira, Simone Muniz Carvalho Fernandes da Cunha, Marlone Cunha da Silva, Liliana Sampaio Costa Mendes, Claudia Alexandra Pontes Ivantes, Liana Codes, Valéria Ferreira de Almeida e Borges, Fabio Heleno de Lima Pace, Mário Guimarães Pessôa, Izabelle Venturini Signorelli, Gabriela Perdomo Coral, Paulo Lisboa Bittencourt, Maria Lucia Gomes Ferraz
- The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascites
- Rasmus Hvidbjerg Gantzel, Thomas Deleuran, Hendrik Vilstrup, Hugh Watson, Peter Jepsen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?